Thyroid receptor ligands and method II

US7288571B2 · kind B2 · utility

Assignee

• Karo Bio AB · SE

Inventors

• Jon J. Hangeland · Levittown, US
• Minsheng Zhang · Hackettstown, US
• Yolanda Caringal · Lawrenceville, US
• Denis E. Ryono · Princeton, US
• Yi Li · Hsinchu, TW
• Johan Malm · Älta, SE
• Ye Liu · Foster City, US
• Neeraj Garg · Tumba, SE
• Chris Litten · Tumba, SE
• Ana Maria Garcia Collazo · Stockholm, SE
• Konrad Koehler · Huddinge, SE

Key dates

• Filing date: Jul 26, 2005
• Grant date: Oct 30, 2007
• Expiry date: Jul 26, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D333/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereolsom thereof; or when n is equal to or greater than one, R4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5—H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependant upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the ex…